Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil.
about
Severe encephalopathy, lactic acidosis, vegetative instability and neuropathy with 5-Fluorouracil treatment - pyrimidine degradation defect or beriberi?Identification of genes conferring resistance to 5-fluorouracilGermline pharmacogenomics in oncology: decoding the patient for targeting therapyPharmacogenomics of chemotherapeutic susceptibility and toxicitybeta-Ureidopropionase deficiency: an inborn error of pyrimidine degradation associated with neurological abnormalitiesInborn errors of pyrimidine metabolism: clinical update and therapyScreening for dihydropyrimidine dehydrogenase deficiency: to do or not to do, that's the questionStrong association of a common dihydropyrimidine dehydrogenase gene polymorphism with fluoropyrimidine-related toxicity in cancer patientsPromoter methylation and large intragenic rearrangements of DPYD are not implicated in severe toxicity to 5-fluorouracil-based chemotherapy in gastrointestinal cancer patients.A case of 5-fluorouracil-induced peripheral neuropathy.New advances in DPYD genotype and risk of severe toxicity under capecitabine.Pharmacogenetic testing through the direct-to-consumer genetic testing company 23andMe.Abdominal irradiation modulates 5-Fluorouracil pharmacokinetics.Absence of large intragenic rearrangements in the DPYD gene in a large cohort of colorectal cancer patients treated with 5-FU-based chemotherapy.Intragenic deletions and a deep intronic mutation affecting pre-mRNA splicing in the dihydropyrimidine dehydrogenase gene as novel mechanisms causing 5-fluorouracil toxicity.Clinical, biochemical and molecular analysis of 13 Japanese patients with β-ureidopropionase deficiency demonstrates high prevalence of the c.977G > A (p.R326Q) mutation [corrected].Dihydropyrimidine dehydrogenase gene as a major predictor of severe 5-fluorouracil toxicity.5-Fluorouracil derivatives: a patent review.Genetic analysis of the first 4 patients with beta-ureidopropionase deficiency.Analysis of pyrimidine catabolism in Drosophila melanogaster using epistatic interactions with mutations of pyrimidine biosynthesis and beta-alanine metabolismOverexpression of the orotate phosphoribosyl-transferase gene enhances the effect of 5-fluorouracil on gastric cancer cell lines.Predictive and prognostic biomarkers with therapeutic targets in breast, colorectal, and non-small cell lung cancers: a systemic review of current development, evidence, and recommendation.Clinically relevant genetic variations in drug metabolizing enzymes.Genetic effects and modifiers of radiotherapy and chemotherapy on survival in pancreatic cancer.Gender-specific acute organ toxicity during intensified preoperative radiochemotherapy for rectal cancer.5-Fluorouracil/irinotecan induced lethal toxicity as a result of a combined pharmacogenetic syndrome: report of a case.Genotyping of a family with a novel deleterious DPYD mutation supports the pretherapeutic screening of DPD deficiency with dihydrouracil/uracil ratio.Engineering of lipid prodrug-based, hyaluronic acid-decorated nanostructured lipid carriers platform for 5-fluorouracil and cisplatin combination gastric cancer therapyConstruction of possible integrated predictive index based on EGFR and ANXA3 polymorphisms for chemotherapy response in fluoropyrimidine-treated Japanese gastric cancer patients using a bioinformatic methodDihydropyrimidine dehydrogenase activity and the IVS14+1G>A mutation in patients developing 5FU-related toxicity.Prospective clinical trials using a pharmacogenetic/pharmacogenomic approach.Dihydropyrimidine dehydrogenase polymorphisms and fluoropyrimidine toxicity: ready for routine clinical application within personalized medicine?Predictive diagnostics in colorectal cancer: impact of genetic polymorphisms on individual outcomes and treatment with fluoropyrimidine-based chemotherapy.Seizures and epilepsy in oncological practice: causes, course, mechanisms and treatmentAdjuvant therapies for colorectal cancer.Polymorphisms of UGT1A1*6, UGT1A1*27 & UGT1A1*28 in three major ethnic groups from MalaysiaThe use of capecitabine in daily practice: a study on adherence and patients' experiencesBeating the odds: efficacy and toxicity of dihydropyrimidine dehydrogenase-driven adaptive dosing of 5-FU in patients with digestive cancer.Association between mRNA expression of chemotherapy-related genes and clinicopathological features in colorectal cancer: A large-scale population analysisProcess map proposal for the validation of genomic biomarkers.
P2860
Q24635885-D654E75E-B732-4607-8426-E403923D5EF6Q24655818-A5CB7B49-6F89-4E97-966E-9C453C62AA5CQ27022557-D61781EE-788F-491D-AAFE-649385FAD078Q27025558-6D4E5D5E-6190-4146-AED2-1571F92CC4A0Q28115518-0CFB32F8-2BCB-45CF-9EEE-5395ED18E0B8Q28244040-64C8FFF9-4A2F-4B61-AB9F-A63571242F64Q28301967-7F185D56-6DFF-486E-A5E0-D5AD8F3C1969Q28474358-769C6136-A77F-4078-AEBA-70025FDD00C3Q30988828-7918BA82-F5AA-4E55-BA0F-0410036A282FQ33378975-46AF542B-E2AA-486D-84AE-DE10281100DFQ33648195-8EB15386-0819-4B85-A29B-C152E7C74702Q33815409-3DE0083B-7E00-47B4-9A4F-8EC3FD52885FQ33816059-A70B63F5-E5B1-42D9-B924-0A446FD7D9E8Q34026282-993BD875-C039-490B-B292-734F3BEDA3F6Q34134768-52F76B47-97C9-4B56-A1EC-A15234E1BF3BQ34151650-A6F226B0-EACC-435D-AAFD-3216A623F274Q34216563-B36F4746-5CB0-4DD2-9F35-C6AA146A743FQ34253978-211F5D98-167E-4153-A162-93B2EBCF6418Q34576619-7C51FC62-178A-4423-A8A5-DE073F4EA5DEQ34587939-B02CD70F-C04F-49FA-90AF-A872CACCF399Q34604303-BF944971-0A83-4153-9CAA-7ECB73F69552Q34620545-8911349C-6E52-41B9-A8B7-F2B4D1304178Q35032378-270F38C1-5248-429B-8A57-9D04D7F6C026Q35048269-171FFAFC-802E-43AD-85F8-08A503692D82Q35584836-D516AECD-9DD9-4B71-B05E-7DC165B79E35Q35588572-ABFE66D4-B090-443A-87BA-FA30BA937531Q35743233-B7658331-116C-4FAA-99B9-88EDDDBC3444Q35746919-F2B32066-336A-45AD-A3E5-81F4C7350A0DQ35811012-02075511-59B2-4BF0-BA08-1A5F5481C717Q36024590-72D332DD-AB3B-46DF-9F4A-928A02C22FD9Q36028631-7329E0D0-A717-47D5-9844-1D41BAAE62B5Q36117656-933FA9EB-FA9E-4BCF-91AA-3E05613FCE38Q36117701-E46D9315-6238-4EBA-8B63-6329C5F7FA55Q36143358-84EF362C-001C-486B-B401-1BB83B00D86BQ36177963-E78D912D-A7D1-4872-A9CC-2EA17DCB1EE4Q36289700-2FCCC85E-2CDD-47D3-85F6-FC5E159AD3DBQ36358178-C1FF27F5-D1E2-4D57-A8C0-F5250A1B68EBQ36410237-5FEF9D6B-6559-46D2-B67E-35E4633BC250Q36473730-462D7871-4D3C-46A5-9D78-6E230D7C78A3Q36555934-BEE79CDA-DC6E-4086-882D-C2B952F805AA
P2860
Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil.
@ast
Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil.
@en
type
label
Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil.
@ast
Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil.
@en
prefLabel
Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil.
@ast
Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil.
@en
P1476
Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil.
@en
P2093
André B P van Kuilenburg
P304
P356
10.1016/J.EJCA.2003.12.004
P577
2004-05-01T00:00:00Z